Skip to main content
Fig. 3 | BMC Musculoskeletal Disorders

Fig. 3

From: Effects of Osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs

Fig. 3

Influence of rosiglitazone on cell osteogenic or adipogenic differentiation in MMSCs and SMMSCs. A Adipogenic differentiation of MMSCs(a-c) and SMMSCs(d-f) treated with rosiglitazone (10 μM) for 14 days were detected by Oil red-O staining(a, c, d, f) or unstaining (b, e). The bars extend 100 μm (a, d) and 20 μm (b, c, e, f). B The expression of PPARγ2 in MMSCs were measured by RT-qPCR from 0 to 14 days in induction of adipogenic differentiation treat with different dose of rosiglitazone (0.1 μM, 1 μM and 10 μM). 0 μM rosiglitazone as control group., C The expression of PPARγ2 in SMMSCs from 0 to 14 days in induction of adipogenic differentiation treat with rosiglitazone (10 μM). D The expression of OGN in MMSCs and SMMSCs from 0 to 14 days in induction of osteogenic differentiation treat with rosiglitazone (10 μM). 0 μM rosiglitazone as control group. Before differentiation (day 0) served as controls as 1. Each assay was performed in three independent experiments. Data are expressed as mean ± SD from all experiments, as indicated * P < 0.05 and ** P < 0.01

Back to article page